Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treatment with IL-2C to expand Tregs effectively halted hair loss progression in a murine model of alopecia areata.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study reviews the mechanism and potential treatment roles of low-level laser therapy for immune-mediated skin diseases, reporting no new clinical results.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

This study found that specific genetic variations in the IRF2BP2 gene influence fleece structure in sheep, with one variant completely determining coat type and another significantly modifying fiber characteristics, providing valuable insights for improving fleece quality through selective breeding.

This study suggests that fractional infrared technology may effectively improve cervical skin laxity by enhancing dermal thickness without adverse effects in a small pilot group.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This review examines the molecular effects of photobiomodulation therapy, particularly its influence on gene and protein expression related to inflammation and cell functions, but reports no new clinical results.

This study found that innate lymphoid cells-type 1 (ILC1lc) can induce alopecia areata (AA) by disrupting hair follicle immune privilege and causing hair follicle dystrophy and regression in both ex vivo and in vivo settings.

In this study, researchers found that a cold atmospheric plasma-activated hydrogel containing interleukin-2 significantly enhanced hair regeneration in a depilated mouse model, promoting larger hair follicles and faster hair growth phase transition, suggesting it as a potential treatment for hair loss.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This study suggests that low-dose IL-2 and IL-15 may help restore immune tolerance in alopecia areata by maintaining Treg cell function, presenting a potential new treatment strategy.

This paper argues that for lupus management, selective immunotherapies like anifrolumab and belimumab, which specifically target parts of the immune system, offer more effective treatment options compared to older, broad immunosuppressive strategies.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

In this study, researchers identified IL18R+ thymus-resident regulatory T cells in mice, demonstrating their unique molecular features and resistance to age- and stress-induced thymus involution, highlighting IL18 signaling's role in Treg migration and retention.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

This study found that Ishige sinicola ethanol extract and its butanol fraction can protect against lipopolysaccharide-induced muscle atrophy in C2C12 myotubes through antioxidant and anti-inflammatory activities.

This case report found that adding lokivetmab to prednisolone treatment improved and maintained remission of pruritus in a dog with cutaneous epitheliotropic lymphoma.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

This study suggests that interleukin-15 plays a complex role in alopecia areata, potentially contributing to immune infiltration while also protecting against hair follicle immune privilege collapse and promoting hair growth.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.